Actavis Launches U.S. Generic Specialty Injectable Portfolio
News Jan 16, 2015
Actavis plc has announced the launch of a leading portfolio of generic specialty injectable medications to be marketed to hospitals across the United States.
Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa.
Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development.
Many of Actavis' generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals, Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.
"Over the last several years, we have been steadily growing our generic specialty injectable business around the world, marketing products in more than 50 countries," said Brent Saunders, CEO and President of Actavis.
Saunders continued, "With the addition of this diverse portfolio of injectable products to our U.S. portfolio, we will create a leading specialty injectable business within Actavis and immediately become a strong competitor in this important, high-value space. In addition, we will continue to invest in the development of our industry-leading generic injectable pipeline as part of our strategy to drive growth through complex, high-barrier-to-entry products. With our proven, well-established supply chain, experience in hospital sales from our brand anti-infective portfolio and strong existing customer relationships, our specialty injectable business is positioned to be a strong growth driver for our Company going forward."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE